Perspective Therapeutics Valuation Multiples

Perspective Therapeutics Overview

About Perspective Therapeutics

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Founded

1983

HQ

Employees

140

Website

perspectivetherapeutics.com

Sectors

Medical DevicesDeepTechHealthTechBioTech

Financials (LTM)

Revenue: $835K

EBITDA: ($122M)

EV

$439M

Valuation Multiples

Multiples.vc

Start free trial

Perspective Therapeutics Financials

Perspective Therapeutics reported last 12-month revenue of $835K and negative EBITDA of ($122M).

In the same LTM period, Perspective Therapeutics generated $835K in gross profit, ($122M) in EBITDA losses, and had net loss of ($111M).

Perspective Therapeutics P&L

In the most recent fiscal year, Perspective Therapeutics reported revenue of $884K and EBITDA of ($101M).

Perspective Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Perspective Therapeutics Stock Performance

Perspective Therapeutics has current market cap of $609M, and enterprise value of $439M.

Perspective Therapeutics' stock price is $5.35.

Perspective Therapeutics Valuation Multiples

Perspective Therapeutics trades at 525.3x EV/Revenue multiple, and (3.6x) EV/EBITDA.

Perspective Therapeutics Financial Valuation Multiples

As of April 2, 2026, Perspective Therapeutics has market cap of $609M and EV of $439M.

Equity research analysts estimate Perspective Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Perspective Therapeutics has a P/E ratio of (5.5x).

Perspective Therapeutics Margins & Growth Rates

Perspective Therapeutics' revenue in the last 12 month declined by (21%).

Perspective Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.

Perspective Therapeutics Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Perspective Therapeutics M&A Activity

Perspective Therapeutics acquired XXX companies to date.

Last acquisition by Perspective Therapeutics was on XXXXXXXX, XXXXX. Perspective Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Perspective Therapeutics Investment Activity

Perspective Therapeutics invested in XXX companies to date.

Perspective Therapeutics made its latest investment on XXXXXXXX, XXXXX. Perspective Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).